Nonlinear Dynamics and PerkinElmer support market interest in 2D for proteomics by supplying Progenesis SameSpots software with the new Geliance 1000 imager
(Newcastle upon Tyne, UK) Nonlinear Dynamics Ltd, the company meeting the analysis challenges in proteomics, biomarker discovery and clinical diagnostics today announced that PerkinElmer, Inc. (Waltham, USA) will supply Progenesis SameSpots with the Geliance 1000 Imaging System, which was launched at the recent HUPO 6th Annual Congress.
Both companies showcased their complimentary technologies at an event where interest in 2D gel image analysis and proteomics was high. This trend reflects the double-digit sales growth reported in Asia/Pacific by proteomics tool suppliers and market predictions made at the end of 2006*. In addition Nonlinear's own data shows increasing numbers of publications from the Far East that reference 2D gel electrophoresis.
Progenesis SameSpots and the Geliance 1000 support this interest by offering significant increases in speed. The time needed to run enough samples for statistically reliable findings from biological populations has been a major limitation for proteomics; SameSpots offers a solution to this problem using 2D gels. The benefits of the SameSpots workflow, which is faster and simpler than traditional approaches, were highlighted in a recent press release from Nonlinear Dynamics. This described research by the National Cancer Research Institute in Japan where biomarkers were validated on a clinical scale within 12 months of installing Progenesis SameSpots.
The increase in analysis speed available with Progenesis SameSpots compliments the performance of the new Geliance 1000, which is one the fastest imaging systems on the market, able to acquire an image up to five times faster than standard scanning systems.
Will Dracup, CEO of Nonlinear Dynamics said, "The HUPO 6th annual congress in Korea was one of the busiest events for Nonlinear that I have ever been to. We were there alongside our partners, including PerkinElmer, who are helping to take SameSpots into Asia/Pacific against a back-drop of strong interest in 2D gel analysis. Together we have addressed a key challenge in proteomics, the ability to run enough samples for reliable conclusions, with a 2D-based solution. Proteomics now has the potential to achieve even more using this key technique."
* Source: Proteomonitor report from January 4th 2007 where instrument vendors (Applied Biosystems, Waters, Agilent Technologies Thermo Fisher Scientific) cited strong growth in their proteomics businesses for the year and projected strong revenue flow in that segment to continue in 2007. Other industry players said that while proteomics is becoming an increasingly important revenue driver; it is still far from being a mature segment.